mRNA |
Bosutinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0032 |
0.9 |
mRNA |
Crizotinib |
CTRPv2 |
pan-cancer |
AAC |
0.0029 |
0.9 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0034 |
0.9 |
mRNA |
tivozanib |
GDSC1000 |
pan-cancer |
AAC |
-0.0032 |
0.9 |
mRNA |
selumetinib:piperlongumine (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0027 |
0.9 |
mRNA |
valdecoxib |
CTRPv2 |
pan-cancer |
AAC |
0.0027 |
0.9 |
mRNA |
BIBW2992 |
CTRPv2 |
pan-cancer |
AAC |
0.0026 |
0.9 |
mRNA |
Cytarabine |
FIMM |
pan-cancer |
AAC |
0.011 |
0.9 |
mRNA |
Midostaurin |
GDSC1000 |
pan-cancer |
AAC |
-0.0025 |
0.9 |
mRNA |
lenalidomide |
FIMM |
pan-cancer |
AAC |
0.012 |
0.9 |